Safety and pharmacokinetics of the oral iron chelator SP-420 in β-thalassemia.

about

Safety and pharmacokinetics of the oral iron chelator SP-420 in β-thalassemia.

Item

http://www.wikidata.org/entity/Q48306161

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Safety and pharmacokinetics of the oral iron chelator SP-420 in β-thalassemia.

@en

Safety and pharmacokinetics of the oral iron chelator SP-420 in β-thalassemia.

@nl

type

Item

label

Safety and pharmacokinetics of the oral iron chelator SP-420 in β-thalassemia.

@en

Safety and pharmacokinetics of the oral iron chelator SP-420 in β-thalassemia.

@nl

prefLabel

Safety and pharmacokinetics of the oral iron chelator SP-420 in β-thalassemia.

@en

Safety and pharmacokinetics of the oral iron chelator SP-420 in β-thalassemia.

@nl

P1476

Safety and pharmacokinetics of the oral iron chelator SP-420 in β-thalassemia

@en

P2093

Alan R Cohen

http://www.w3.org/2001/XMLSchema#string

Antoine N Saliba

http://www.w3.org/2001/XMLSchema#string

Brenda I Jeglinski

http://www.w3.org/2001/XMLSchema#string

Gregory Berk

http://www.w3.org/2001/XMLSchema#string

Janet L Kwiatkowski

http://www.w3.org/2001/XMLSchema#string

Keith Pietropaolo

http://www.w3.org/2001/XMLSchema#string

Patricia J Giardina

http://www.w3.org/2001/XMLSchema#string

Yesim Aydinok

http://www.w3.org/2001/XMLSchema#string

P2860

Fanconi syndrome in a patient with β-thalassemia major after using deferasirox for 27 months.

The impact of polyether chain length on the iron clearing efficiency and physiochemical properties of desferrithiocin analogues.

Iron-chelating therapy for transfusional iron overload

Desferrithiocin analogue iron chelators: iron clearing efficiency, tissue distribution, and renal toxicity

Design, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analogues.

Deferasirox nephrotoxicity-the knowns and unknowns.

Transfusion-dependent thalassaemic patients with renal Fanconi syndrome due to deferasirox use.

Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox.

Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial.

How I treat transfusional iron overload

P304

1356-1361

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/AJH.24914

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-10-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28940308

http://www.w3.org/2001/XMLSchema#string